Zacks Investment Research upgraded shares of Thermo Fisher Scientific Inc (NYSE:TMO) from a hold rating to a buy rating in a research report sent to investors on Thursday morning. The firm currently has $214.00 target price on the medical research company’s stock.

According to Zacks, “Over the last three months, Thermo Fisher is trading above the broader industry. Thermo Fisher ended the second quarter on a promising note. We are particularly upbeat about the company gaining entry into the CDMO market through the recent acquistion of Patheon for $7.2 billion. We are also encouraged by the company’s series of product launches along with major progress in precision medicine initiatives. Thermo Fisher’s acquisition of FEI Company has already started to boost its analytical instruments portfolio. The company also opened Center of Excellence for electron microscopy in Saudi Arabia. The raised 2017 guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through the year.”

TMO has been the subject of a number of other reports. Cleveland Research raised shares of Thermo Fisher Scientific from a neutral rating to a buy rating in a research report on Thursday, July 20th. Argus restated a buy rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Morgan Stanley restated an overweight rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. BidaskClub cut shares of Thermo Fisher Scientific from a strong-buy rating to a buy rating in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC reiterated a hold rating and issued a $175.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, May 17th. One equities research analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $193.56.

Thermo Fisher Scientific (NYSE TMO) traded down 0.54% during trading on Thursday, reaching $190.65. The company’s stock had a trading volume of 1,346,337 shares. The company has a market cap of $74.38 billion, a P/E ratio of 33.21 and a beta of 1.05. The stock’s 50-day moving average is $179.77 and its 200 day moving average is $170.30. Thermo Fisher Scientific has a 12 month low of $139.07 and a 12 month high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.27 by $0.03. The company had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.03 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific will post $9.35 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) Upgraded to “Buy” by Zacks Investment Research” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/15/thermo-fisher-scientific-inc-tmo-upgraded-to-buy-by-zacks-investment-research.html.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 10.45%.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total transaction of $736,092.00. Following the transaction, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,738 shares of company stock worth $4,021,512. 0.49% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in Thermo Fisher Scientific by 2,692.1% during the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after acquiring an additional 22,165,530 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Thermo Fisher Scientific by 29.8% during the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after buying an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Thermo Fisher Scientific by 2,058.1% during the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after buying an additional 2,233,522 shares during the last quarter. C WorldWide Group Holding A S lifted its position in shares of Thermo Fisher Scientific by 997.1% during the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock valued at $299,527,000 after buying an additional 1,772,300 shares during the last quarter. Finally, Veritas Asset Management LLP lifted its position in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after buying an additional 1,286,259 shares during the last quarter. Hedge funds and other institutional investors own 83.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.